SIREN : 884638214
SPECTRE BIOTECH is a French company founded 5 years ago, specialized in the sector Edition de logiciels applicatifs. Based in CHESSY (77700), this company of category PME shows in 2021 a revenue of 6 k€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Data updated on 2026-05-02
Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy
| Indicator | 2025 | 2023 | 2021 |
|---|---|---|---|
| Revenue | N/C | N/C | 5 960 € |
| Net income | 0 € | 0 € | -1 877 € |
| EBITDA | N/C | N/C | -1 066 € |
| Net margin | N/C | N/C | -31.5% |
In 2025, SPECTRE BIOTECH records a net loss of 0 €. This deficit will reduce equity on the balance sheet.
The debt ratio (= Financial debt / Equity x 100) stands at 7%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches 6%. Low autonomy: the company heavily depends on external financing (banks, suppliers).
7.352%
6.4%
26.9%
In 2025, the debt ratio of SPECTRE BIOTECH (7.35) ranks above the median of the sector. This ratio measures the weight of debt relative to equity. A reduction effort could improve financial strength.
In 2025, the financial autonomy of SPECTRE BIOTECH (6.4%) ranks in the bottom 25% of the sector. This ratio represents the share of equity in total financing. Low autonomy may limit investment capacity and increase vulnerability.
In 2021, the repayment capacity of SPECTRE BIOTECH (0.00) ranks in the bottom 25% of the sector, which is positive. This ratio indicates the number of years needed to repay debt with cash flow. A short capacity reflects controlled debt and good cash generation.
The liquidity ratio (= Current assets / Current liabilities) stands at 649.78. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.
649.779
In 2025, the liquidity ratio of SPECTRE BIOTECH (649.78) ranks in the top 25% of the sector. This ratio measures the ability to cover short-term debt with current assets. A ratio above 1 ensures comfortable coverage of short-term maturities.
In 2021, the interest coverage of SPECTRE BIOTECH (0.0x) ranks below the median of the sector. This ratio indicates how many times operating income covers interest expenses. An improvement would strengthen the competitive position.
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments.
0 €
0 j
0 j
0 j
Compare SPECTRE BIOTECH with other companies in the same sector:
Voir toutes les statistiques du secteur Edition de logiciels applicatifs
The revenue of SPECTRE BIOTECH in 2021 is 6 k€.
SPECTRE BIOTECH recorded a net loss in 2021.
The headquarters of SPECTRE BIOTECH is located in CHESSY (77700), in the department Seine-et-Marne.
The tax return of SPECTRE BIOTECH is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
SPECTRE BIOTECH operates in the sector Edition de logiciels applicatifs (NAF code 58.29C). See the 'Sector positioning' section above to compare the company with its competitors.